Jesy Nelson, a former member of the beloved girl group Little Mix, has shared a heart-wrenching revelation about her twin daughters' health. In a recent Instagram video, Nelson disclosed that her precious baby girls, Ocean Jade and Story Monroe, have been diagnosed with a devastating genetic condition, Spinal Muscular Atrophy (SMA). This condition, she explained, could mean her daughters may never walk.
But here's where the story takes a turn: Nelson's daughters were born prematurely last May, and since then, she's noticed their limited leg movement and feeding difficulties. After months of uncertainty and countless appointments, the diagnosis of SMA Type 1 was confirmed. This form of SMA is particularly severe, attacking the body's muscles over time and, if left untreated, reducing a baby's life expectancy to just two years.
The singer was told by specialists at Great Ormond Street Hospital in London that her daughters would likely never walk and may never regain their neck strength, leaving them disabled. However, there's a glimmer of hope. Nelson shared that her daughters have received treatment, which she believes will save their lives. She's even had to step into the role of a nurse, using breathing machines to support her daughters' health.
The past few months have been an emotional rollercoaster for Nelson, who feels her life has been turned upside down. Yet, she remains optimistic, believing her daughters will beat the odds. She wants to use her platform to raise awareness and help other children receive timely diagnoses.
Nelson's journey to motherhood has been challenging. She gave birth to her twins prematurely at 31 weeks and previously shared that her pregnancy was complicated. Despite these struggles, she expressed immense pride in her body and the strength it has given her as a mother.
Jesy Nelson's time in Little Mix ended in December 2020, and she has since pursued a solo career, releasing the single 'Boyz' featuring Nicki Minaj in 2021. SMA is a cruel disease, but there is a ray of hope in the form of a gene therapy drug called Zolgensma, approved by the NHS in 2021. This drug offers a healthy gene copy to the body, potentially slowing the disease's progression.
SMA UK is advocating for the inclusion of SMA in a blood spot test for newborns, as early detection is crucial. While SMA is rare, affecting approximately 47 babies in the UK in 2024, the altered gene is carried by one in 40 people. This means many more individuals could be unknowingly affected.
And here's where it gets controversial: Should SMA screening be expanded to include all newborns, or is the current approach sufficient? What are your thoughts on the balance between early detection and potential anxiety for parents? Share your opinions below, and let's spark a thoughtful discussion.
